NovelStem Intl (NSTM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NSTM SEC filings page.
This page shows NovelStem Intl Corp (NSTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported balance sheet shifted from lightly burdened to liability-heavy, while recurring operations remain difficult to evaluate from disclosed figures.
From FY2022 to FY2025, total assets fell99.3% while total liabilities rose510.6% . That reversal left FY2025 with negative equity of-$2.1M and a near-zero current ratio of 0.0x, making the reported capital structure the central financial fact visible in the statements.
In FY2023, a net loss of
Financing cash inflows were
Financial Health Signals
We do not publish a peer-relative financial health score for NovelStem Intl Corp, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
NovelStem Intl Corp reported a net loss of $86K in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
NovelStem Intl Corp earned $0.00 per diluted share (EPS) in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
NovelStem Intl Corp held $56K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
NSTM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| SG&A Expenses | $35K-45.4% | $5K-94.8% | N/A | $39K-93.0% | $64K-55.6% | $95K-48.4% | N/A | $567K+572.8% |
| Operating Income | -$35Kn/m | -$5Kn/m | N/A | -$39Kn/m | -$64Kn/m | -$95Kn/m | N/A | -$564Kn/m |
| Interest Expense | $51K+41.3% | $36K-68.0% | N/A | $44K-58.5% | $36K-66.2% | $113K+18.9% | N/A | $105K+270.2% |
| Net Income | -$86K | -$55Kn/m | N/A | N/A | N/A | -$207Kn/m | N/A | N/A |
| EPS (Basic) | $0.00-100.0% | $0.00n/m | $0.00n/m | N/A | $0.06n/m | $0.00n/m | $0.00n/m | -$0.05n/m |
| EPS (Diluted) | $0.00-100.0% | $0.00n/m | $0.00n/m | N/A | $0.06n/m | $0.00n/m | $0.00n/m | -$0.05n/m |
| Diluted Shares (Avg) | 49M+3.3% | 47M+1.1% | N/A | 47M0.0% | 48M+1.9% | 47M0.0% | N/A | 47M0.0% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Income Tax.
NSTM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $65K+323.0% | $101K-32.7% | $16K-90.1% | $15K-92.5% | $15K-99.3% | $150K-93.8% | $160K-92.9% | $198K-90.2% |
| Current Assets | $65K+323.0% | $101K+364.0% | $16K-50.5% | $15K-78.5% | $15K-46.8% | $22K-39.7% | $32K-63.2% | $69K+37.9% |
| Cash & Equivalents | $56K+4984.5% | $90K+2541.9% | $333-94.5% | $627-98.6% | $1K-85.9% | $3K-34.4% | $6K-88.5% | $45K+550.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $11K | $8K |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.1M+5.4% | $2.0M-62.7% | $2.2M-59.3% | $2.1M-60.2% | $2.0M-59.2% | $5.5M+18.3% | $5.3M+26.1% | $5.2M+28.6% |
| Current Liabilities | $2.1M | N/A | $2.2M-59.3% | N/A | N/A | N/A | $5.3M+1431.0% | $3.6M+84.2% |
| Non-Current Liabilities | $0 | N/A | $0n/m | N/A | N/A | N/A | $0-100.0% | $1.6M-23.6% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $106K |
| Total Equity | -$2.0Mn/m | -$1.9Mn/m | -$2.1Mn/m | -$2.1Mn/m | -$2.0Mn/m | -$5.3Mn/m | -$5.1Mn/m | -$5.0Mn/m |
| Retained Earnings | -$294.1Mn/m | -$294.0Mn/m | -$294.0Mn/m | -$293.9Mn/m | -$293.8Mn/m | -$296.6Mn/m | -$296.4Mn/m | -$296.2Mn/m |
Not reported in any period shown, so not listed: Inventory, Goodwill.
NSTM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$34Kn/m | -$139Kn/m | -$26Kn/m | -$31Kn/m | -$67Kn/m | -$44Kn/m | -$39Kn/m | -$63Kn/m |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | $9K-35.2% | N/A | $9K-47.1% |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Financing Cash Flow | $0-100.0% | $228K+456.7% | $26Kn/m | $30K-69.5% | $65K-35.5% | $41K-85.1% | $0-100.0% | $100K+122.2% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NSTM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NovelStem Intl Corp NSTM | FY2025 | N/A | N/A | N/A | $345K | — |
| Hypha Labs, Inc. FUNI | FY2025 | N/A | N/A | N/A | $570K | — |
| ProPhase Labs Inc PRPH | FY2025 | $4.3M | -$14.7M | N/A | $111K | — |
| Avricore Health Inc AVCRF | FY2024 | $3.3M | -$465K | -14.0% | $101K | — |
Where NovelStem Intl Corp Ranks
Frequently Asked Questions
NovelStem Intl Corp (NSTM) had $16K in total assets as of fiscal year 2025, including both current and long-term assets.
NovelStem Intl Corp (NSTM) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
NovelStem Intl Corp (NSTM) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $345K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
NovelStem Intl Corp (NSTM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $345K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
NovelStem Intl Corp (NSTM) has negative shareholder equity of -$2.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.